FDA Needs Alternative To Labels To Change Behavior, IoM Safety Cmte. Says
Executive Summary
FDA needs to develop a more proactive tool to change prescribing behavior rather than relying on labeling, panelists said at the Jan. 17 meeting of the Institute of Medicine's Committee on the Assessment of the U.S. Drug Safety System
You may also be interested in...
FDA Needs Quantitative Risk/Benefit Analysis To Quell Industry Approval Fears
Quantitative measures to evaluate drug risks and benefits would provide FDA a stronger defense against critiques of regulatory decisions, several agency observers suggested
FDA Needs Quantitative Risk/Benefit Analysis To Quell Industry Approval Fears
Quantitative measures to evaluate drug risks and benefits would provide FDA a stronger defense against critiques of regulatory decisions, several agency observers suggested
FDA Should Reassess Patient Information Sheet Proposal, NCPIE Says
FDA should rethink its proposal for agency-issued patient information sheets, National Council on Patient Information & Education Exec VP Ray Bullman said at a recent hearing on drug safety communications